Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Hugues Sicotte

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0304-8515; OpenAlex author ID A5007577734. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Germline Variants in Chronic Pancreatitis-Associated Genes and Risk of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2026.03.043↗
  2. Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0343022↗
  3. Bulk RNA-seq deconvolution heterogeneity across paired pancreatic cancer human samples. Last author DOI 10.3389/fgene.2025.1662924↗
  4. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Co-author DOI 10.1016/j.jbc.2021.100634↗
  5. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  6. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  7. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  8. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Co-author DOI 10.1038/ejhg.2010.198↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kari G. Rabe · 7 shared papers, 2011–2026 · strength 1.03
  2. Samuel O. Antwi · 5 shared papers, 2018–2026 · strength 0.89
  3. Ann L. Oberg · 3 shared papers, 2020–2026 · strength 0.50
  4. Gloria M. Petersen · 5 shared papers, 2011–2021 · strength 0.43
  5. Rick J. Jansen · 1 shared paper, 2025 · strength 0.33
  6. Jason W. Hoskins · 1 shared paper, 2026 · strength 0.27
  7. Katelyn E. Connelly · 1 shared paper, 2026 · strength 0.27
  8. Khalid Jazieh · 1 shared paper, 2026 · strength 0.27
  9. Ryan Michael Carr · 1 shared paper, 2026 · strength 0.27
  10. Laufey Thora Amundadottir · 1 shared paper, 2026 · strength 0.27
  11. Aminah Jatoi · 2 shared papers, 2020–2021 · strength 0.23
  12. Lisa A. Boardman · 2 shared papers, 2020–2021 · strength 0.23
  13. Martín E. Fernández-Zapico · 2 shared papers, 2018–2021 · strength 0.16
  14. Amit Mahipal · 1 shared paper, 2021 · strength 0.13
  15. Hu Li · 1 shared paper, 2021 · strength 0.10
  16. Renzo Emanuel Vera · 1 shared paper, 2021 · strength 0.10
  17. Isaac P. Horn · 1 shared paper, 2021 · strength 0.10
  18. Katrina Sophia Pedersen · 2 shared papers, 2011–2018 · strength 0.09
  19. Robert R. McWilliams · 2 shared papers, 2011–2018 · strength 0.09
  20. Lang Wu · 1 shared paper, 2018 · strength 0.06
  21. William J. Blot · 1 shared paper, 2018 · strength 0.06
  22. Wei Zheng · 1 shared paper, 2018 · strength 0.06
  23. Donghui Li · 1 shared paper, 2018 · strength 0.06
  24. Jeanine M. Genkinger · 1 shared paper, 2018 · strength 0.06
  25. Jennifer B. Permuth · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.